The Total number of records shown on this page is 100. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
OV_4165	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4166	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	1 MOI	20% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4167	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	1 MOI	15% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4168	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	1 MOI	2% cell viability after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4169	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MCF-7	5000 cells per well	NA	MTT assay	1 MOI	100% cell killing after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4170	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4171	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	90% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4172	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	70% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4173	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	40% cell viability after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4174	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	30% cell viability after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4175	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4176	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	50% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4177	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	20% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4178	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	10% cell viability after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4179	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	10% cell viability after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4180	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4181	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	80% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4182	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	58% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4183	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	20% cell viability after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4184	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	100% cell killing after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4185	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4186	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	50% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4187	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	10% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4188	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	100% cell killing after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4189	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	100% cell killing after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4190	Measles virus	MV-lambda-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing human lambda immunoglobulin chain	Yes	No	No	NA	NA	NA	NA	NA	NA	NA	NA	Female athymic nude mice xenograft for MDA-231-lu-P4 (1.0E+6 cells)	2.0E+6 TCID50	NA	All mice dead after 100 days	Intravenous	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4191	Measles virus	MV-lambda-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing human lambda immunoglobulin chain	No	Virus in combination with Alisertib 30mg/kg for 3 weeks	No	NA	NA	NA	NA	NA	NA	NA	NA	Female athymic nude mice xenograft for MDA-231-lu-P4 (1.0E+6 cells)	2.0E+6 TCID50	NA	Mice median survival time increased to 82.5 days compared to control	Intravenous	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4192	Measles virus	MV-lambda-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing human lambda immunoglobulin chain	Yes	No	No	NA	NA	NA	NA	NA	NA	NA	NA	Female athymic nude mice xenograft for MDA-231-lu-P4 (2.0E+6), pleural effusion transthoracic cavity	5.0E+5 TCID50	NA	Mice median survival increased to 57 days	Transthoracic	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4193	Measles virus	MV-lambda-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing human lambda immunoglobulin chain	Yes	Virus in combination with Alisertib 30mg/kg for 3 weeks	No	NA	NA	NA	NA	NA	NA	NA	NA	Female athymic nude mice xenograft for MDA-231-lu-P4 (2.0E+6), pleural effusion transthoracic cavity	5.0E+5 TCID50	NA	Mice median survival increased to 74 days compared to control 57 days	Transthoracic	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4242	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	ABC-1	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	100% cell viability after day 1	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4243	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	ABC-1	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	80% cell viability after day 3	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4244	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	ABC-1	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	60% cell viability after day 5	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4245	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	ABC-1	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	45% cell viability after day 7	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4246	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	National institute of biomedical innovation, Japan	Human nonsmall cell lung carcinoma cell line	NCI-H441	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	100% cell viability after day 1	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4247	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	National institute of biomedical innovation, Japan	Human nonsmall cell lung carcinoma cell line	NCI-H441	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	80% cell viability after day 3	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4248	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	National institute of biomedical innovation, Japan	Human nonsmall cell lung carcinoma cell line	NCI-H441	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	35% cell viability after day 5	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4249	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	National institute of biomedical innovation, Japan	Human nonsmall cell lung carcinoma cell line	NCI-H441	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	100% cell killing after day 7	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4250	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	ATCC	Human nonsmall cell lung carcinoma cell line	NCI-H2170	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	90% cell viability after day 1	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4251	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	ATCC	Human nonsmall cell lung carcinoma cell line	NCI-H2170	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	38% cell viability after day 3	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4252	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	ATCC	Human nonsmall cell lung carcinoma cell line	NCI-H2170	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	20% cell viability after day 5	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4253	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	ATCC	Human nonsmall cell lung carcinoma cell line	NCI-H2170	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	100% cell killing after day 7	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4254	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	ATCC	Human nonsmall cell lung carcinoma cell line	NCI-H358	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	100% cell viability after day 1	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4255	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	ATCC	Human nonsmall cell lung carcinoma cell line	NCI-H358	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	55% cell viability after day 3	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4256	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	ATCC	Human nonsmall cell lung carcinoma cell line	NCI-H358	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	30% cell viability after day 5	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4257	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	ATCC	Human nonsmall cell lung carcinoma cell line	NCI-H358	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	20% cell viability after day 7	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4258	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	Calu-3	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	100% cell viability after day 1	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4259	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	Calu-3	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	80% cell viability after day 3	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4260	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	Calu-3	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	42% cell viability after day 5	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4261	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	Calu-3	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	30% cell viability after day 7	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4262	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	ATCC	Human nonsmall cell lung carcinoma cell line	NCI-H1666	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	100% cell viability after day 1	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4263	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	ATCC	Human nonsmall cell lung carcinoma cell line	NCI-H1666	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	60% cell viability after day 3	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4264	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	ATCC	Human nonsmall cell lung carcinoma cell line	NCI-H1666	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	40% cell viability after day 5	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4265	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	ATCC	Human nonsmall cell lung carcinoma cell line	NCI-H1666	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	25% cell viability after day 7	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4266	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	PC-14	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	100% cell viability after day 1	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4267	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	PC-14	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	100% cell viability after day 3	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4268	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	PC-14	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	100% cell viability after day 5	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4269	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	PC-14	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	80% cell viability after day 7	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4270	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	A431	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	100% cell viability after day 1	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4271	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	A431	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	100% cell viability after day 3	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4272	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	A431	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	100% cell viability after day 5	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4273	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	Human nonsmall cell lung carcinoma cell line	A431	5.0E+3 cells per well	NA	WST-1 assay	1 MOI	80% cell viability after day 7	No	No	NA	No response	NA	NA	NA	NA	26317644
OV_4274	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	NA	NA	NA	NA	NA	NA	NA	SCID mice xenograft for NCI-H441 cell (5.0E+6)	1.0E+6 TCID50	NA	Reduction in tumor volume 500 cubic millimeter after 40 days compared to control 2500 cubic millimeter	Intratumoral	NA	NA	NA	26317644
OV_4633	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	Univesity of Tokyo Japan	Canine mammary cancer	CF33	NA	NA	WST-1 assay	2 MOI	50% cell viability after 2 days	No	No	NA	No response	NA	NA	NA	NA	27093696
OV_4634	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	Univesity of Tokyo Japan	Canine mammary cancer	CF33	NA	NA	WST-1 assay	2 MOI	30% cell viability after 4 days	No	No	NA	No response	NA	NA	NA	NA	27093696
OV_4635	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	Univesity of Tokyo Japan	Canine mammary cancer	CF33	NA	NA	WST-1 assay	2 MOI	35% cell viability after 6 days	No	No	NA	No response	NA	NA	NA	NA	27093696
OV_4636	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	Univesity of Tokyo Japan	Canine mammary cancer	CF33	NA	NA	WST-1 assay	2 MOI	30% cell viability after 8 days	No	No	NA	No response	NA	NA	NA	NA	27093696
OV_4637	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	Univesity of Tokyo Japan	Canine mammary cancer	CTBm	NA	NA	WST-1 assay	2 MOI	100% cell viability after 2 days	No	No	NA	No response	NA	NA	NA	NA	27093696
OV_4638	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	Univesity of Tokyo Japan	Canine mammary cancer	CTBm	NA	NA	WST-1 assay	2 MOI	80% cell viability after 4 days	No	No	NA	No response	NA	NA	NA	NA	27093696
OV_4639	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	Univesity of Tokyo Japan	Canine mammary cancer	CTBm	NA	NA	WST-1 assay	2 MOI	60% cell viability after 6 days	No	No	NA	No response	NA	NA	NA	NA	27093696
OV_4640	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	Univesity of Tokyo Japan	Canine mammary cancer	CTBm	NA	NA	WST-1 assay	2 MOI	50% cell viability after 8 days	No	No	NA	No response	NA	NA	NA	NA	27093696
OV_4641	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	Univesity of Tokyo Japan	Canine mammary cancer	CHMm	NA	NA	WST-1 assay	2 MOI	100% cell viability after 2 days	No	No	NA	No response	NA	NA	NA	NA	27093696
OV_4642	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	Univesity of Tokyo Japan	Canine mammary cancer	CHMm	NA	NA	WST-1 assay	2 MOI	40% cell viability after 4 days	No	No	NA	No response	NA	NA	NA	NA	27093696
OV_4643	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	Univesity of Tokyo Japan	Canine mammary cancer	CHMm	NA	NA	WST-1 assay	2 MOI	40% cell viability after 4 days	No	No	NA	No response	NA	NA	NA	NA	27093696
OV_4644	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	Univesity of Tokyo Japan	Canine mammary cancer	CHMm	NA	NA	WST-1 assay	2 MOI	40% cell viability after 4 days	No	No	NA	No response	NA	NA	NA	NA	27093696
OV_4645	Measles virus	rMV-SLAMblind	RNA	Paramyxoviridae	R533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle	Yes	No	No	NA	NA	NA	NA	NA	NA	NA	NA	SCID mice xenograft for CF33 cells	1.0E+6 TCID50	NA	Reduction in tumor volume below 100 cubic mm after 50 days compared to control 700 cubic mm	Intratumoral	NA	NA	NA	27093696
OV_5387	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human rhabdomyosarcoma cell line	RD	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu	40% cell growth inhibition after 72 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5388	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human rhabdomyosarcoma cell line	RD	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, one fold dilution	56.778% cell growth inhibition after 72 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5389	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human rhabdomyosarcoma cell line	RD	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, two fold dilution	60.493% cell growth inhibition after 72 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5390	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human rhabdomyosarcoma cell line	RD	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, three fold dilution	38.616% cell growth inhibition after 72 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5391	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human rhabdomyosarcoma cell line	RD	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, four fold dilution	31.039% cell growth inhibition after 72 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5392	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human rhabdomyosarcoma cell line	RD	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, five fold dilution	19.801% cell growth inhibition after 72 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5393	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human rhabdomyosarcoma cell line	RD	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, one fold dilution	53.110% cell growth inhibition after 120 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5394	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human rhabdomyosarcoma cell line	RD	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, two fold dilution	69.954% cell growth inhibition after 120 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5395	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human rhabdomyosarcoma cell line	RD	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, three fold dilution	53.717% cell growth inhibition after 120 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5396	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human rhabdomyosarcoma cell line	RD	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, four fold dilution	31.714% cell growth inhibition after 120 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5397	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human rhabdomyosarcoma cell line	RD	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, five fold dilution	15.174% cell growth inhibition after 120 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5398	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human rhabdomyosarcoma cell line	RD	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, six fold dilution	5.918% cell growth inhibition after 120 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5399	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human glioblastoma cell line	ANGM5	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu	46.047% cell growth inhibition after 72 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5400	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human glioblastoma cell line	ANGM5	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, one fold dilution	46.047% cell growth inhibition after 72 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5401	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human glioblastoma cell line	ANGM5	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, two fold dilution	73.183% cell growth inhibition after 72 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5402	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human glioblastoma cell line	ANGM5	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, three fold dilution	58.012% cell growth inhibition after 72 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5403	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human glioblastoma cell line	ANGM5	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, four fold dilution	27.350% cell growth inhibition after 72 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5404	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human glioblastoma cell line	ANGM5	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, five fold dilution	19.658% cell growth inhibition after 72 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5405	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human glioblastoma cell line	ANGM5	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, six fold dilution	14.529% cell growth inhibition after 72 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5406	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human glioblastoma cell line	ANGM5	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, one fold dilution	87.81% cell growth inhibition after 120 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5407	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human glioblastoma cell line	ANGM5	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, two fold dilution	90.101% cell growth inhibition after 120 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5408	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human glioblastoma cell line	ANGM5	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, three fold dilution	74.746% cell growth inhibition after 120 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5409	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human glioblastoma cell line	ANGM5	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, four fold dilution	48.477% cell growth inhibition after 120 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5410	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human glioblastoma cell line	ANGM5	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, five fold dilution	36.421% cell growth inhibition after 120 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663
OV_5411	Measles virus	Schwarz vaccine stain	RNA	Paramyxoviridae	None	Yes	No	No	ICCMGR cell bank unit, Iraq	Human glioblastoma cell line	ANGM5	7.0E+3 cells per well	NA	MTT assay	3.4 × 10⁵ pfu, six fold dilution	23.477% cell growth inhibition after 120 hours	No	No	NA	No response	NA	Induction of apoptosis as measured by mitochondrial permeability apoptosis assay	NA	NA	27512663